MEDIUM confidence: 100% data completeness, but the composite (58) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $12.9B— | $13.8B+6.7% | $15.2B+9.9% | $17.5B+15.3% | $18.0B+3.0% |
| EPS (dil.) | $3.83— | $4.60+20.3% | $3.73-19.0% | $3.43-8.0% | $4.04+17.8% |
| Free Cash Flow | $3.0B— | $2.4B-20.1% | $274M-88.5% | $2.9B+963.1% | $2.7B-8.4% |
| Gross Margin | 44.3% | 45.7%+1.4pp | 49.0%+3.3pp | 50.8%+1.8pp | 52.8%+2.0pp |
| Operating Margin | 15.1% | 17.1%+1.9pp | 18.2%+1.1pp | 15.2%-3.0pp | 19.6%+4.4pp |
| Net Margin | 17.8% | 23.4%+5.6pp | 87.2%+63.8pp | 11.3%-75.9pp | 12.7%+1.5pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $169 (last qtr, 8 analysts) → $174 (last mo, 4) (+2.7%).
Buy-rated share 62% → 66% over ~3 months (+3pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $1.68 | $1.71 | +1.8% |
| May 2026 | $1.53 | $1.54 | +0.7% |
| Feb 2026 | $1.42 | $1.46 | +2.8% |
| Nov 2025 | $1.62 | $1.62 | +0.0% |
| Aug 2025 | $1.51 | $1.52 | +0.7% |
| May 2025 | $1.41 | $1.48 | +5.0% |
| Feb 2025 | $1.28 | $1.38 | +7.8% |
| Nov 2024 | $1.47 | $1.48 | +0.7% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 6.0%/yr (revenue basis).
Base free cash flow $2.0B (avg FY2023–FY2025; latest year $2.7B) · equity value $90.3B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider -$5.2M over 180 days (0 open-market buys, 4 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 58 for EMR indicates a moderately attractive stock, with the short-term score of 61 being slightly higher than the long-term score of 56. EMR scores high on momentum, driven by its 21.4% return over the past year and a bullish 50-day versus 200-day moving average trend. However, the stock trades at a premium, as reflected in its value score of 53, with a P/E of 35.1 and EV/EBITDA of 19.8, and its growth score of 48 is held back by negative free cash flow growth.